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Background: Accumulated data from previous studies appear to suggest a link between the overexpression of a
35 kDa fragment of serum inter-alpha-trypsin inhibitor H4 (ITIH4) with cancers that are associated with up-regulated
levels of oestrogens. The truncated fragment was postulated to be a product of oestrogen-induced action of
kallikrein on native ITIH4. The present lectin-based proteomic analyses were performed to assess the specificity of
the 35 kDa fragment of ITIH4 as a potential cancer biomarker and determine whether it was also overexpressed in
the sera of cancer-negative pregnant women who are known to have high levels of plasma oestrogens.
Results: Our results demonstrated that the 35 kDa fragment of ITIH4 was overexpressed in healthy pregnant
women and patients with hydatidiform mole, relative to the controls. The serum oestradiol levels of both groups of
pregnant subjects were also confirmed to be higher than those of the control women who were not pregnant.
Conclusions: Overexpression of the 35 kDa fragment of ITIH4 was not restrictive to patients with cancers but also
occurred in women who were pregnant and those diagnosed with hydatidiform mole. Our data implicate the
limitation of the 35 kDa ITIH4 fragment as a cancer biomarker and its correlation with serum oestrogen levels.Background
Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) is a
member of the inter-alpha-trypsin inhibitor (ITI) family
of hepatic origin [1,2]. It is the only member of the ITI
family which harbours a kallikrein-released bradykinin-like
domain in its C-terminal sequence [3], making it plasma
kallikrein sensitive [4-6]. Trace amounts of plasma kalli-
krein have been shown to cleave ITIH4 to yield two frag-
ments, i.e., a 35 kDa C-terminal polypeptide and an
85 kDa N-terminal fragment [7]. The 35 kDa ITIH4 frag-
ment, which is O-glycosylated [3,8], is assumed to remain
intact. However, the 85 kDa ITIH4 fragment is further
cleaved to produce an N-terminal 57 kDa fragment and a* Correspondence: onnhashim@um.edu.my
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distribution, and reproduction in any mediumputative 28 kDa fragment. The latter is believed to be fur-
ther processed by protease(s) to generate smaller frag-
ments [8].
We have previously analyzed the expression of the
35 kDa ITIH4 fragment in groups of patients with nine dif-
ferent types/subtypes of cancers using the gel-based prote-
omics approach and a lectin that binds to O-glycosylated
proteins [9-12]. Whilst the serum ITIH4 fragment was
demonstrated to be overexpressed in patients with endo-
metrial cancer, ovarian cancer (germ-line and epithelial
ovarian carcinoma) and breast cancer compared to the
control subjects, its levels were not significantly different in
sera of patients with nasopharyngeal carcinoma, osteosar-
coma (localized disease), cervical cancer (squamous cell
cervical carcinoma and cervical adenocarcinoma) and
prostate cancer [9-11]. In the latter cancer, however, signifi-
cantly enhanced levels of a similar ITIH4 fragment was
later detected in the urine of the patients [12].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Serum oestradiol levels. Serum samples were subjected
to quantitative measurements of oestradiol levels as described in the
Methods section. All values are presented as mean ± SEM.
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cancers that are associated with overexpression of the
35 kDa ITIH4 fragment with those that did not is that
the former also appears to be associated with the up-
regulated levels of serum oestrogens [13,14]. This is sug-
gestive of the potential use of the ITIH4 fragment as a
complementary biomarker for oestrogen-related cancers.
However, enhanced blood oestrogen levels are not re-
strictive to patients with cancer but also occur in healthy
women who are pregnant as well as those detected with
benign tumours. Hence, the present study was carried
out to assess the specificity of the 35 kDa ITIH4 frag-
ment as a potential biomarker for cancer and whether it
was also overexpressed in two groups of cancer-negative
women who were pregnant and are known to have high
levels of plasma oestrogens. The first group of subjects
comprised healthy pregnant women, whilst the second
were those who were diagnosed with hydatidiform mole,
a type of gestational trophoblastic disease that is associ-
ated with a rare mass or growth that forms inside the
uterus at the beginning of a pregnancy.
Results
Determination of serum oestradiol levels
The present study was performed to assess the specifi-
city of the 35 kDa fragment of ITIH4 as a potential can-
cer biomarker and determine whether it was overexpressed
in the sera of pregnant women (n = 20) and patients with
hydatidiform mole (n = 20), who are known to have higher
levels of serum oestrogens, relative to normal healthy sub-
jects (n = 20). To confirm for the altered levels of serum
oestrogens in the women who were pregnant and those
with hydatidiform mole compared to the controls, their
serum samples were analysed for their oestradiol levels
as described in the Methods section. Figure 1 demon-
strates that the mean levels of serum oestradiol were signifi-
cantly higher in the women who were pregnant (4816 ±
610 pmol/L) and those with hydatidiform mole (3468 ±
1955 pmol/L), compared to the controls (393 ± 91 pmol/L).
Two-dimensional electrophoretic profiles of serum
O-glycosylated proteins
In this study, the expression of a 35 kDa ITIH4 fragment,
which is O-glycosylated, was analysed using an earlier
established method involving two-dimensional gel electro-
phoresis (2-DE), western blotting and the use of champedak
galactose binding (CGB) lectin to detect O-glycosylated
proteins [9-12]. The CGB lectin was chosen on the basis of
its specific interaction with O-glycans [15,16].
Figure 2 demonstrates representative 2-DE serum O-
glycosylated protein profiles of (a) control subjects, (b)
healthy pregnant women and (c) patients with hydatidiform
mole that were resolved using enzyme-conjugated CGB lec-
tin. A total of six clusters of O-glycosylated serum proteinswere consistently detected in all the lectin-developed pro-
files, whilst several others had low rates of presence in the
2-DE gels. Like most other serum glycopeptides, the
35 kDa cleavage fragment of ITIH4 were separated into a
cluster of five isoform spots because of its heterogeneous
glycan structures. Both groups of women sera that were
studied demonstrated enhanced expression of the 35 kDa
ITIH4 fragment cluster relative to that of the non-pregnant
healthy women controls.Identification of ITIH4 fragment spot cluster
The identity of ITIH4 fragment spot cluster was con-
firmed by subjecting the serum protein to MALDI ToF/
ToF analysis and search of the Swiss-Prot database
(Table 1). Whilst the database search indicates that the
spot cluster of interest was that of ITIH4, the approxi-
mate experimental molecular weight that was derived
from migration of the protein in the 2-DE protein pro-
files suggests that it was a truncated 35 kDa fragment of
the polypeptide.Image analysis of O-glycosylated ITIH4 fragment
When the 35 kDa serum ITIH4 fragment cluster was
analysed by densitometry, significant up-regulated ex-
pression was detected in the women who were pregnant
(+8.7-fold; p = 0.0002) as well as in the patients with hyda-
tidiform mole (+5.6-fold; p < 0.0001) relative to the controls
(Figure 3). This is comparable with values that were ob-
tained for patients with endometrial cancer, germ-line and
epithelial ovarian cancers, and breast cancer [9,10].
Figure 2 Detection of 2-DE separated ITIH4 fragment on
nitrocellulose membrane. Neat serum samples were subjected to
2-DE, western blotting and detection with enzyme-conjugated
CGB lectin. Panel (a) demonstrates a typical profile of healthy
non-pregnant women controls, while panels (b) and (c) are
representative profiles of healthy pregnant women and patients
with hydatidiform mole, respectively. The cleavage fragment of ITIH4
(ITIH4f) appears to be overexpressed in all subjects’ profiles relative
to the controls. For all panels, the acidic side of the blot is to the left
and relative molecular mass declines from the top.
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Our previous accumulated studies have demonstrated
the overexpression of a 35 kDa ITIH4 fragment select-
ively in cancers associated with elevated oestrogen levels,
including cancers of the breast, endometrium, ovary and
prostate but not in nasopharyngeal carcinoma, osteosar-
coma and cervical cancer. To investigate the possibilityTable 1 Confirmation of the identity of serum ITIH4 by MS/M







(a)ITIH4 spot cluster was a fragment based on its estimated experimental molecularthat the 35 kDa ITIH4 fragment may also be enhanced
in non-cancer conditions that are associated with up-
regulated levels of oestrogens, analysis was extended to
include two groups of non-cancer patients with similar hor-
monal dysregulation. In the present study, two groups of
women with different pregnancies and with increased levels
of oestrogens were chosen. The first group comprised
healthy women who were pregnant, which represents a
normal condition, while the second involved patients with
hydatidiform mole and represents a benign condition.
The maternal levels of circulating oestrogens increase
continuously throughout a normal pregnancy, as it is re-
quired to support foetal development [17-19]. This is also
seen when the healthy women subjects who were preg-
nant were analysed for their serum oestrogens in the
present study. Similarly, women with hydatidiform mole
have also been reported to have plasma oestrogen levels as
high as those with normal pregnancy [20] and this is also
reflected from their serum oestradiol values that were de-
termined in this study.
When sera of both groups of pregnant subjects were
analysed using an earlier established CGB lectin-based
electrophoretic approach in the present study, the ex-
pression of the 35 kDa ITIH4 fragment was prominently
up-regulated compared to the controls. The fold differ-
ences obtained for the healthy pregnant women and pa-
tients with hydatidiform mole were comparable with
those that were earlier established for patients with en-
dometrial cancer, germ-line and epithelial ovarian can-
cers, and breast cancer (Figure 4). Hence, these results,
when taken together with the data of the previous stud-
ies, generally indicate that the overexpression of the
35 kDa ITIH4 fragment was not exclusive to oestrogen-
related cancers but also occurs in normal pregnancy and
benign conditions.
The marked difference in the expression of the 35 kDa
ITIH4 cleavage fragment detected in the various subjects
with enhanced oestrogen levels may be attributed to the
increased cleavage of ITIH4 by elevated levels of circu-
lating kallikreins in the serum. The idea that the abun-
dance of the ITIH4 fragment is linked to high amounts
of serum kallikreins is derived from previous reports
demonstrating overexpression of members of the kalli-
krein family in cancers of the breast, ovary and endo-
metrium [21-23]. This is not surprising as kallikreins are
known to be expressed in hormone-dependant tissues
such as the breast and ovary [24]. In addition, theS
tical
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Figure 3 Expression of 35 kDa ITIH4 fragment in sera of
women with normal pregnancy and hydatidiform mole. Analysis
was performed on sera of healthy non-pregnant women controls
(n = 20) and healthy pregnant women (NP; n = 20) and those with
hydatidiform mole (HM; n = 20). Expression of ITIH4 fragment was
analysed in terms of the percentage of volume contribution, which
refers to the spot volume of the glycoprotein expressed as a
percentage of the total spot volume of all detected serum
glycoproteins. All values are presented as mean ± SEM. Data were
analyzed by Student’s t-test and a p value of less than 0.01 was
considered significant. Asterisks denote significantly different values
as compared to controls.
Mohamed et al. Biomarker Research 2013, 1:19 Page 4 of 6
http://www.biomarkerres.org/content/1/1/19expression of the kallikrein genes have been shown to be
regulated by steroid hormones (including oestrogens) in
cancer cell lines [22,25]. As the ITIH4 protein is kallikrein-
sensitive, there is likelihood that the overexpression of kal-
likrein may lead to increased cleavage of serum ITIH4
which in turn led to the enhanced liberation of its 35 kDa
C-terminal fragment. In support of this correlation is
a study conducted by Gangadharan et al. [26], which
showed that the down-regulation of kallikrein in patients
with hepatic cirrhosis resulted in low abundance of the
ITIH4 fragments including the 35 kDa fragment.Figure 4 Relative expression of ITIH4 fragment in serum
samples. Fold-differences calculated for healthy pregnant women
(NP) and those with hydatidiform mole (HM) are values relative to
the expression of ITIH4 fragment in the control subjects. Values for
patients with breast cancer (BrCa), endometrial cancer (EACa),
epithelial ovarian cancer (EOCa) and germ-line ovarian cancer
(GOCa) were those that had been previously reported [9,10].Conclusions
The data of the present study, when taken together with
those of our previous reports, suggest that overexpression
of the 35 kDa fragment of ITIH4 is oestrogen-related and
occurs in patients with selective cancers, hydatidiform
mole as well as healthy women who are pregnant. This
implicates the limitation of the ITIH4 fragment as a bio-
marker for cancer.
Methods
Collection of serum samples
Serum samples were collected with patients’ consent at the
Obstetrics and Gynaecology ward, University of Malaya
Medical Centre (UMMC), Kuala Lumpur in accordance to
a protocol that was approved by the Medical Ethics Com-
mittee of the centre. Samples from groups of women who
were pregnant (n = 20) and patients with hydatidiform mole
(n = 20) were collected in their first trimester of pregnancy.
For comparison, sera from normal healthy non-pregnant
women (n = 20) were obtained from age-matched volun-
teers (range of 21–45 years). Blood samples were collected
in fresh 1.5 ml BD vacutainers (Becton, Dickinson & Co,
Franklin Lakes, New Jersey, USA) and were centrifuged at
3000 g for 10 min (Centrifuge 5403, Eppendorf, Hamburg,
Germany). Serum was collected and stored in aliquots of
100 μl at −80° until used.
Biochemical tests
Quantitative measurements of oestradiol in the subjects’
serum samples were performed according to the manufac-
turer’s instructions using the ADVIA Centaur and ADVIA
Centaur XP Systems (Siemens Medical Solutions Diagnos-
tics, Tarrytown, USA). Values of serum oestradiol are ex-
pressed in mean ± SEM.
2-DE
2-DE was performed as previously described [27] using
approximately 800 μg protein. Neat serum samples were
initially incubated in 2% v/v IPG sample buffer pH 4–7,
containing 9 M urea, 60 mM DTT, and 0.5% v/v Triton
X-100 at room temperature for 30 min. They were then
incubated in a rehydration solution containing 8 M urea,
0.5% v/v IPG buffer, 0.5% v/v Triton X-100 for another
30 min before incubating with rehydrated IPG Immobiline
Drystrips pH 4–7, 11 cm (GE Healthcare, Uppsala,
Sweden) overnight. The strips were subjected to isoelec-
tric focusing using the Multiphor Flatbed electrophoresis
system (GE Healthcare, Uppsala, Sweden) for a total dur-
ation of 15 kV/h (Phase 1: 300 V, 2 mA, 5 W, 30 min;
Phase 2: 3500 V, 2 mA, 5 W, ∼4–4.5 h). Focused strips
were equilibrated in 1.5 M Tris–HCl (pH 8.8) solution
containing 6 M urea, 2% w/v SDS, 30% v/v glycerol, and
0.06 M DTT for 15 min on a UNIMAX 2010 platform
shaker and further incubated in a similar equilibration
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DTT for another 15 min. The equilibrated strips were
overlaid onto 8-18% gradient polyacrylamide gels and
electrophoresis was performed following an optimized
protocol (Phase 1: 50 V, 40 mA, 25 W for 30 min; Phase
2: 600 V, 40 mA, 25 W for 1–2 h) using the SE 600 Ruby
Electrophoresis System and Power Supply-EPS601 (GE
Healthcare, Uppsala, Sweden).
Western blotting and detection of O-glycosylated proteins
The 2-DE-separated proteins were transferred electrophor-
etically onto nitrocellulose (NC) membranes (0.45 mM;
Whatman, Dassel, Germany) using the NovaBlot Kit of the
Multiphor™ II Flatbed System (GE Healthcare, Uppsala,
Sweden) for 2 h at a constant current of 0.8 mA/cm2 gel.
Detection of transferred O-glycosylated serum proteins was
performed using the CGB lectin that was affinity purified
and characterized for its specificity to O-glycans using
methods that were previously reported [28]. The lectin was
then conjugated to horseradish peroxidase before being
used to probe for O-glycopeptides on the NC membranes.
The membranes were finally developed by means of a col-
orimetric reaction using diamino-benzoic acid as substrates.
Mass spectrometry
Protein spots of interest were carefully excised from the
blot for the subsequent on-membrane trypsin digestion
according to method that was previously described [29].
The MS/MS analysis was performed using the 4800 Plus
MALDI ToF/ToF analyzer (Applied Biosystems, Foster
City, CA, USA).
Database search
Identification of proteins was performed using the MAS-
COT search engine [30]. The MS data obtained was
searched against Homo sapien entries in the Swiss-Prot
database (Last update: February 15, 2012, containing
535248 sequences) according to the following selection
parameters: enzyme - trypsin, missed cleavage - 1, vari-
able modification - 2; i) carbamidomethylation of cyst-
eine and ii) oxidation of methionine, MS precursor ion
mass tolerance - 100 ppm, MS/MS fragment ion mass
tolerance - 0.2 Da, and inclusion of monoisotopic
masses only.
Image analysis
CGB lectin-probed NC blots were scanned using Imaging
Densitometer GS690 (Bio-Rad Laboratories, Hercules,
California, USA). Expression of ITIH4 fragment was
analysed in terms of the percentage of volume contribu-
tion, which refers to the spot volume of the glycoprotein
expressed as a percentage of the total spot volume of all
detected serum glycoproteins, using the Image Master 2D
Platinum software, version 7.0 (GE Healthcare Biosciences,Uppsala, Sweden). Cut-off parameters were: Smooth – 2;
Saliency – 1; Min area – 5. Data expressed in this manner
are independent of variations attributed to protein loading
and staining.
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